What The Study Did: Using insurance claims data, the change in screening rates for breast, colorectal and prostate cancers during the COVID-19 pandemic were estimated as well as the overall decline in cancer screening last year among the U.S. population.
Authors: Ronald Chen, M.D., M.P.H., of the University of Kansas in Kansas City, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaoncol.2021.0884)
Editor's Note: The article includes conflicts of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
###
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2021.0884?guestAccessKey=2e43ed34-0a44-4101-9dae-319f9a2c065c&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=042921
JAMA Oncology